Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 2/20 | 0.50 |
| ▸ | AKT2 | P31751 | 1/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.43 |
| ▸ | KDR | P35968 | 4/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.42 |
| ▸ | PRKACA | P17612 | 3/20 | 0.42 |
| ▸ | CDK8 | P49336 | 3/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.42 |
| ▸ | MAP2K1 | Q02750 | 3/20 | 0.42 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.42 |
| ▸ | CSF1R | P07333 | 2/20 | 0.42 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.42 |
| ▸ | JAK2 | O60674 | 2/20 | 0.42 |
| ▸ | RET | P07949 | 2/20 | 0.42 |
| ▸ | GSK3A | P49840 | 2/20 | 0.42 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.42 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15106830 | 0.77 | AKT1 (0.50) | AKT1AKT2PIK3CDKDRMAP4K4 | |
| SCHEMBL529936 | 0.75 | AKT1 (0.52) | AKT1AKT2PIK3CDDYRK1AMAPT | |
| SCHEMBL530189 | 0.71 | CDK2 (0.40) | AKT1AKT2KDRKDM4EADRA2A | |
| SCHEMBL135824 | 0.70 | CHRM5 (0.40) | AKT1PIK3CDKDRMAP4K4PRKACA | |
| SCHEMBL360789 | 0.70 | DYRK1A (0.77) | KDRMAP4K4PRKACACDK8CLK4 | |
| SCHEMBL1665644 | 0.70 | APOBEC3A (0.54) | AKT1AKT2KDRMAP4K4PRKACA | |
| SCHEMBL14126501 | 0.69 | AKT1 (0.52) | AKT1AKT2MAP4K4DYRK1BAURKA | |
| SCHEMBL19322369 | 0.68 | AKT1 (0.50) | AKT1AKT2PIK3CDKDRMAP4K4 | |
| SCHEMBL2646928 | 0.68 | GABRA1 (0.52) | MAP4K4CLK4DYRK1BLRRK2JAK2 | |
| SCHEMBL28502974 | 0.67 | PIK3CD (0.39) | PIK3CDKDRMAP4K4PRKACACDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987273-B2 | Substituted imidazo[1,2-B]pyridazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| US-8987273-B2 | Substituted imidazo[1,2-B]pyridazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| US-8987273-B2 | Substituted imidazo[1,2-B]pyridazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| EP-2598505-B1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES | BAYER IP GMBH (DE) | 2015-03-18 | — | — | EP | disclosed |
| EP-2598505-B1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES | BAYER IP GMBH (DE) | 2015-03-18 | — | — | EP | disclosed |
| US-20130210825-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-08-15 | — | — | US | disclosed |
| US-20130210825-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-08-15 | — | — | US | disclosed |
| US-20130210825-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-08-15 | — | — | US | disclosed |
| EP-2598505-A2 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES | Bayer Intellectual Property GmbH (DE) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012013713-A2 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210825-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES | NRAS, IDH2, NDUFB1 | AKT1 4494/4885AKT2 4136/4885PIK3CD 1958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.